Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Brigatinib, a next-generation ALK (Anaplastic Lymphoma Kinase) Inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m)(?id=bd9ff631-3ee3-4bd6-9322-590f30c5f41d&linkText=Non-Small-Cell+Lung+Carcinoma+%28NSCLC%29+%28ALK+m%29 at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial. The results of the second prespecified interim analysis, which includes 150 events, are reported (1)
An ope…